Skip to main content

Advertisement

Log in

Antimicrobial susceptibility of Enterococcus strains used in clinical practice as probiotics

  • Original Article
  • Published:
Journal of Infection and Chemotherapy

Abstract

The aim of this study was to evaluate the antimicrobial susceptibilities of probiotic strains that are suggested to be effective for preventing antibiotics-associated diarrhea (AAD). The minimum inhibitory concentrations (MICs) of 17 antibiotics against probiotic strains were tested by the agar plate dilution method or broth microdilution method. In all, eight probiotic strains containing Enterococcus faecalis, Bifidobacterium spp., Clostridium butyricum, and Lactobacillus acidophilus were tested. Although the MIC range was wide, from less than 0.0625 to more than 1,024 μg/ml, the MICs of 11 beta-lactams were high for three of four enterococci, with a range of 32 to more than 1,024 μg/ml. In contrast, fluoroquinolones and vancomycin showed potent activities against all enterococci, of which MICs were 0.25–8 μg/ml. Two Bifidobacterium strains and one Lactobacillus strain showed low MICs against many of the beta-lactams, fluoroquinolones, macrolides, and vancomycin, with MICs of 8 μg/ml or less. Fosfomycin showed generally mild activity against enterococci (MIC, 8–32 μg/ml) and anaerobic strains (MIC, 32 to >1,024 μg/ml), respectively. The probiotics strains with high MIC values may survive in the intestinal tract, even if the patient was concomitantly using the antibiotics in clinical practice. Therefore, our results suggest that adequate combinations of probiotics strains and antibiotics should be important for preventing AAD. Further study is needed to determine the efficacy of probiotics in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Surawicz CM. Antibiotic-associated diarrhea and pseudomembranous colitis: are they less common with poorly absorbed antimicrobials? Chemotherapy. 2005;51(suppl 1):81–9.

    Article  PubMed  CAS  Google Scholar 

  2. Saavedra JM. Probiotics plus antibiotics: regulating our bacterial environment. J Pediatr. 1999;135:535–7.

    Article  PubMed  CAS  Google Scholar 

  3. Bartlett JG. Antibiotic-associated diarrhea. Clin Infect Dis. 1992;15:573–81.

    Article  PubMed  CAS  Google Scholar 

  4. Kelly CP, LaMont JT. Clostridium difficile infection. Annu Rev Med. 1998;49:375–90.

    Article  PubMed  CAS  Google Scholar 

  5. Anand A, Bashey B, Mir T, Glatt AE. Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea. Am J Gastroenterol. 1994;89:519–23.

    PubMed  CAS  Google Scholar 

  6. Al-Eidan FA, McElnay JC, Scott MG, Kearney MP. Clostridium difficile-associated diarrhea in hospitalized patients. J Clin Pharm Ther. 2000;25:101–9.

    Article  PubMed  CAS  Google Scholar 

  7. Gogate A, De A, Nanivadekar R, Mathur M, Saraswathi K, Jog A, et al. Diagnostic role of stool culture and toxin detection in antibiotic associated diarrhea due to Clostridium difficile in children. Indian J Med Res. 2005;122:518–24.

    PubMed  CAS  Google Scholar 

  8. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis. 1998;26:1027–34.

    Article  PubMed  CAS  Google Scholar 

  9. Johnston BC, Supina AL, Ospina M, Vohra S. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2007;18:CD004827

    Google Scholar 

  10. Avadhani A, Miley H. Probiotics for prevention of antibiotic-associated diarrhea and Clostridium difficile-associated disease in hospitalized adults. A meta-analysis. J Am Acad Nurse Pract. 2011;23:269–74.

    Article  PubMed  Google Scholar 

  11. Moubareck C, Gavini F, Vaugien L, Butel MJ, Doucet-Poupulaire F. Antimicrobial susceptibility of bifidobacteria. J Antimicrob Chemother. 2005;55:38–44.

    Article  PubMed  CAS  Google Scholar 

  12. Masco L, Van Hoorde K, De Brandt E, Swings J, Huys G. Antimicrobial susceptibility of Bifidobacterium strains from humans, animals and probiotic products. J Antimicrob Chemother. 2006;58:85–94.

    Article  PubMed  CAS  Google Scholar 

  13. Miller M. The fascination with probiotics for Clostridium difficile infection: lack of evidence for prophylactic or therapeutic efficacy. Anaerobe. 2009;15:281–4.

    Article  PubMed  Google Scholar 

  14. Musgrave CR, Bookstaver PB, Sutton SS, Miller AD. Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection. Int J Infect Dis. 2011;15:e438–48.

    Article  PubMed  CAS  Google Scholar 

  15. Parkes GC, Sanderson JD, Whelan K. The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhea. Lancet Infect Dis. 2009;9:237–44.

    Article  PubMed  Google Scholar 

  16. Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacterial that grow aerobically: approved standard. Eighth edition. CLSI document M07-A8. Wayne, PA: CLSI; 2009

  17. Clinical and Laboratory Standards Institute (CLSI). Methods for antimicrobial susceptibility testing of anaerobic bacteria: approved standard. Seventh edition. CLSI document M11-A7. Wayne, PA: CLSI; 2007

  18. Iwata S, Kawahara K, Isohata E, Kin Y, Yokota T, Kusumoto Y, et al. Effect of meropenem on fecal flora in children. Jpn J Antibiot. 1992;45:1385–402.

    Article  PubMed  CAS  Google Scholar 

  19. Iwata S, Yamamoto K, Isohata E, Kin Y, Yokota T, Kusumoto Y, et al. Effect of biapenem (L-627) on fecal flora in gnotobiotic mice and children. Jpn J Antibiot. 1994;47:1668–84.

    PubMed  CAS  Google Scholar 

  20. Nakashima M, Uematsu T, Kanamaru M, Okazaki O, Hakusui H. Phase I study of levofloxacin, (s)-(−)-ofloxacin. Jpn J Clin Pharmacol Ther. 1992;23:515–20.

    Article  CAS  Google Scholar 

  21. Nord CE, Brismar B, Kasholm-Tengve B, Tunevall G. Effect of piperacillin/tazobactam therapy on intestinal microflora. Scand J Infect Dis. 1992;24:209–13.

    Article  PubMed  CAS  Google Scholar 

  22. MotohiroT, Masunaga K, Ootu Y, Ikezawa S, Matsuo Y, Maruoka T, et al. Influence of tazobactam/piperacillin on human fecal flora. Chemotherapy 1994;42(suppl 2):300–317

  23. Sekino H, Nakamichi N, Niida Y, Matsumoto S, Yokokawa M. Pharmacokinetic and tolerability study 600 mg of biapenem (BIPM) administered repeatedly. Kiso to Rinsho. 1996;30:3265–82.

    Google Scholar 

  24. Condon ER, Walker PA, Hanna BC, Greenberg NR, Broom A, Pitkin D. Penetration of meropenem in plasma and abdominal tissues from patients undergoing intraabdominal surgery. Clin Infect Dis. 1997;24(suppl 2):S181–3.

    Article  PubMed  CAS  Google Scholar 

  25. Edmiston CE, Krepel CJ, Seabrook GR, Towne JB, Smith TL, Loehrl TA, et al. Tissue and fluid penetration of garenoxacin in surgical patients. Surg Infect (Larchmt). 2007;8:179–88.

    Article  Google Scholar 

  26. Neu HC. Third generation cephalosporins: safety profiles after 10 years of clinical use. J Clin Pharmacol. 1990;30:396–403.

    Article  PubMed  CAS  Google Scholar 

  27. Koizumi Y, Kimura T, Hatanaka S, Kadotani M, Takahashi Y. Risk factors for the induction of antibiotic-associated diarrhea. Jpn J Environ Infect. 2008;23:175–80.

    Article  Google Scholar 

  28. Courvalin P. Antibiotic resistance: the pros and cons of probiotics. Dig Liver Dis. 2006;38(suppl 2):S261–5.

    Article  PubMed  Google Scholar 

  29. Werner G, Coque TM, Hammerum AM, Hope R, Hryniewicz W, Johnson A, et al. Emergence and spread of vancomycin resistance among enterococci in Europe. Euro Surveill 2008;13(47):19046

    Google Scholar 

  30. French GL. Enterococci and vancomycin resistance. Clin Infect Dis. 1998;27(suppl 1):S75–83.

    Article  PubMed  CAS  Google Scholar 

  31. Floch MH, Walker WA, Madsen K, Sanders ME, Macfarlane GT, Flint HJ, et al. Recommendations for probiotic use: 2011 update. J Clin Gastroenterol. 2011;45(suppl):S168–71.

    Article  PubMed  Google Scholar 

  32. Japan Medical Data Center. The information of precise estimates of the number of receiving drugs. http://www.jmdc.co.jp/en/srv_pharma/scene.html#souyaku. 2013.

Download references

Acknowledgments

We appreciate Hideyuki Sasaoka and Takahiro Morishita (Department of Microbiology, Bunkyo Gakuin University), and Toshie Fukui (Department of Microbiology, Tokyo Medical University) for their helpful expertise in our experiments.

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tetsuya Matsumoto.

About this article

Cite this article

Yamaguchi, T., Miura, Y. & Matsumoto, T. Antimicrobial susceptibility of Enterococcus strains used in clinical practice as probiotics. J Infect Chemother 19, 1109–1115 (2013). https://doi.org/10.1007/s10156-013-0633-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10156-013-0633-6

Keywords

Navigation